Background: Liquid biopsy is a minimally invasive detection method for molecular biomarkers
such as miRNA and cell free DNA in body fluids. Deregulations of miRNA are involved in
papillary thyroid carcinoma (PTC), one the most common endocrine malignancy. The most widespread
common mutations detected in papillary thyroid cancers are BRAF mutations. Many studies indicate
that the BRAF mutation is related to deregulation of miRNA. p53 has an important role in cell
cycle control, DNA repair and apoptosis. Moreover, the p53 can regulate the expression of miRNAs
and thus participate in thyroid oncogenesis.
Objective: In this review, we briefly summarize the present state of knowledge about miRNA, BRAF
and p53 mutation in the development of PTC and the possibility of using detecting BRAF mutation
and miRNA expression in liquid biopsy.
Results: The use of the plasma miRNA expression profile in combination with the BRAF mutation
analysis in cf-DNA may be a valuable tool in management of PTC.
Conclusion: Numerous molecular variation characterize recent diagnostic and prognostic markers and
therapeutic targets for this type of cancer, which offer unique chances for further research and clinical
development of innovative treatment strategies for thyroid cancer.